PD-L1 Expression Quantitation via Modified H and Proportion Scores
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quantifying PD-L1 expression in tumor tissue sections are inadequate for accurately predicting patient response to anti-PD-1 therapy due to complexity in staining patterns, necessitating the development of new scoring rules for reliable quantitation across multiple tissue samples.
Innovation Solution
A novel scoring process involving a modified H score (MHS) and modified proportion score (MPS) is introduced, where tissue sections are stained with an anti-PD-L1 antibody, and specific percentages of stained cells are assigned to calculate these scores, allowing for standardized quantitation and designation of tumor samples as positive or negative for PD-L1 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If simple binary end-point scoring (positive/negative) is used for PD-L1 expression, then the assessment is quick and easy, but it lacks precision in predicting patient response to therapy
Solution Approach 1:
The patent changes the scoring parameters from a simple binary system to a multi-parameter system that includes percentage of stained cells, staining intensity, and cellular location (tumor cells vs. immune cells). This allows for more precise measurement of PD-L1 expression while maintaining a standardized scoring framework that can be operationally implemented.
2Adaptability or versatility
If different scoring approaches are used by different pathologists, then individual judgment flexibility is maintained, but consistency and reliability across multiple tissue samples deteriorate
Solution Approach 1:
The patent establishes homogeneous scoring criteria that all pathologists must follow, including standardized definitions for staining intensity levels, consistent methods for calculating percentage of stained cells, and uniform rules for distinguishing tumor cells from immune cells. This ensures reliable and consistent scoring across multiple pathologists and tissue samples while still allowing for professional judgment within the standardized framework.
3Loss of information
If PD-L1 expression is quantified in both tumor cells and infiltrating immune cells separately, then comprehensive expression information is obtained, but the complexity of the scoring process increases
Solution Approach 1:
The patent segments the scoring process into distinct components: scoring tumor cells separately from immune cells, evaluating different staining intensity levels independently, and calculating separate percentages for each cell type. This segmentation allows for comprehensive capture of PD-L1 expression information while organizing the complexity into manageable, systematic steps that can be followed consistently.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This scoring process provides valuable predictive information for identifying patients likely to respond to anti-PD-1 therapy by standardizing PD-L1 expression quantitation, facilitating the selection of appropriate treatment regimens.
Implementation Method 1
stained in an immunohistochemical (IHC) assay with an antibody that specifically binds to the PD-L1 protein
Data Source
AI summary
The present disclosure provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections as detected by immunohistochemical assay using an antibody that specifically binds to PD-L1. The results generated using these processes have a variety of experimental, diagnostic and prognostic applications.